TY - JOUR
T1 - Cancer immunotherapy in patients with preexisting autoimmune disorders
AU - Donia, Marco
AU - Pedersen, Magnus
AU - Svane, Inge Marie
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Patients with preexisting active autoimmune disorders were excluded from clinical trials of immune checkpoint inhibitors. However, patients with autoimmune disorders are diagnosed with cancer at least as frequently as the global population, and clinicians treating patients outside clinical trials have generally been reluctant to offer cancer immunotherapy to this patient group. In this brief article, we review the most recent literature on the efficacy and safety of CTLA-4- and PD-1-blocking antibodies in patients with preexisting autoimmune disorders.
AB - Patients with preexisting active autoimmune disorders were excluded from clinical trials of immune checkpoint inhibitors. However, patients with autoimmune disorders are diagnosed with cancer at least as frequently as the global population, and clinicians treating patients outside clinical trials have generally been reluctant to offer cancer immunotherapy to this patient group. In this brief article, we review the most recent literature on the efficacy and safety of CTLA-4- and PD-1-blocking antibodies in patients with preexisting autoimmune disorders.
KW - Antibodies, Monoclonal/adverse effects
KW - Antineoplastic Agents/adverse effects
KW - Autoimmune Diseases/complications
KW - B7-H1 Antigen/antagonists & inhibitors
KW - CTLA-4 Antigen/antagonists & inhibitors
KW - Humans
KW - Immune Tolerance
KW - Immunosuppression
KW - Immunotherapy/adverse effects
KW - Molecular Targeted Therapy/adverse effects
KW - Neoplasms/complications
KW - Neoplasms, Second Primary/etiology
KW - Programmed Cell Death 1 Receptor/antagonists & inhibitors
KW - Risk
KW - Treatment Outcome
U2 - 10.1007/s00281-016-0595-8
DO - 10.1007/s00281-016-0595-8
M3 - Review
C2 - 27730287
SN - 1863-2297
VL - 39
SP - 333
EP - 337
JO - Seminars in Immunopathology
JF - Seminars in Immunopathology
IS - 3
ER -
